Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
FSGS: early-phase trial registry
5 of 5 indexed FSGS trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
FSGS: 5 US clinical trials tracked, 5 recruiting.
FSGS is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan, running 2 of these trials.
Enrollment posture brief
Registry condition fsgs
OPEN 5 | RECR 100% | LATE 1 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
FSGS lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for FSGS on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
FSGS is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates FSGS research.
University of Michigan accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical FSGS enrolment sits around 286 participants.
Median target enrolment is 286 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
FSGS research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
NEPTUNE Match Study
University of Michigan
NCT04571658
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
University of Michigan
NCT05650619
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Dimerix Bioscience Pty
NCT05183646
Atacicept in Multiple Glomerular Diseases
Vera Therapeutics
NCT06983028
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
Alice Bertaina
NCT05508009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on FSGS records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on FSGS trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this FSGS page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 FSGS trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Michigan sponsors the most FSGS trials on record, review their full trial history before evaluating a specific study. See University of Michigan's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This FSGS condition card totals 5 registered trials; most-linked intervention Communication; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.